ARS Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $3.83 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $7.94, a 90.41% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.17, a 155.83% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.63, a 37.79% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.62, a 113.01% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $3.62, a 97.81% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.83, a 33.70% decline from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.76, a 165.38% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.04.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.83 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $7.94 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $3.62 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $3.92 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $4.07 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $4.17 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $1.83 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $1.86 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $1.25 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $1.63 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $2.76 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $2.73 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $3.00 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $2.62 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $1.04 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $2.04 10-Q · filed 2022-11-02 | |||
| 2022-06-30 | $1.24 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $1.23 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $2.65 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $2.86 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $2.18 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |